TipBros

27/07/2020

The United States has doubled its investment - to nearly US$1 billion - to expedite development of a potential COVID-19 vaccine by American firm Moderna, which on Monday (Jul 27) begins the decisive final phase of clinical trials.

The United States has doubled its investment - to nearly US$1 billion - to expedite development of a potential COVID-19 vaccine by American firm ...

19/07/2020

Moderna(MRNA) to Join the NASDAQ-100 Index Beginning July 20, 2020

How Does Index Rebalancing Affect Individual Stocks?

With the rise of ETFs and index investing, there’s been a greater focus on the addition and subtraction of stocks from indices, including those that are widely followed, such as the $DJI, SPX, and Nasdaq-100 (NDX).

This is because many institutional investors attempt to mirror the performance of these indices by buying the same stocks.

Some funds are even required by their charter or offering prospectus to hold the same stocks.

Why do stock indices change their components and what happens when there's a change?

19/07/2020

Moderna’s vaccine for COVID-19 showed it was safe and triggered immune responses in all 45 healthy volunteers in an ongoing early-stage study.

Moderna shares have gained a whopping 283.6% this year due to successful early-stage clinical trials for COVID-19 vaccine, winning a place on the Nasdaq-100 with the company's sheer success.

21/06/2020

Traders alert! Watch out for Moderna(MRNA)’s breakout!

30/05/2020

The U.S. population could rise from about 330 million today to more than 360 million by the decade’s end, depending on a bunch of social and economic factors, such as future immigration levels. Different age groups will get vaccinated at differing rates—hopefully unimpeded by antivaccination sentiments. BMO estimates that will work out to about 30% of America’s head count getting vaccinated each year, or some 100 million treatments a year by the second half of this decade. Put a price from $30 to $130 on those numbers, and you get $3 billion to $13 billion in U.S. sales.

A third of the developed world’s population could get vaccinated every year. That could amount to a $10 billion annual business, at an estimated price of $30 per vaccination. At higher prices, Covid vaccine revenue would be bigger still.

20/05/2020

In the Short-Run, the Market Is a Voting Machine, But in the Long-Run, the Market Is a Weighing Machine

19/05/2020

Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results.

The new price target implies a 25% leap from Moderna's price. Goldman Sachs Analyst Salveen Richter raised the vaccine's probability of success to 75% from 70%.

Moderna Inc. got a new Wall Street-high price target from Goldman Sachs as its shares traded at a record after the biotech company revealed positive early results from its experimental vaccine for Covid-19.

24/04/2020

The Moderna vaccine was the first of more than 70 candidate vaccines currently being tested worldwide, according to the World Health Organization.

The volunteers who got shots in the first trial of a possible coronavirus vaccine are getting the second shot — an indicator the trial is going well.

21/04/2020

The federal government is betting almost half a billion dollars, USD$484 million, on a potential coronavirus vaccine being developed by Cambridge biotechnology company Moderna.

A grant, worth as much as $483 million, will help Moderna continue to manufacture large amounts of its potential vaccine and create a ready supply of the drug, if it turns out to work.

26/03/2020

What can go wrong if you give up on the stock market?

If it’s any consolation during these trying times, most trials are finite. Even aggressive, stock-heavy portfolios took just around two years to fully recover from the last financial crisis, Charles Schwab found.

It can feel impossible to imagine a different reality than the one we’re engulfed in. Yet we’ve been hit with disasters and devastation before, and the market has always bounced back. Why give up on it now?

People are giving up on the stock market amid the coronavirus outbreak. They'll likely regret it.

03/02/2020

Want to increase your stock market returns but unsure who to trust/follow?

Are stock analysts, corporate insiders, bloggers reliable and accurate? What is their track record? And most importantly – should I listen to this particular “expert”?

TipBros is Asia's first mobile app that allows investors to see the track record and measured performance of stock analysts, corporate insiders and bloggers so you can make better investment decisions.

Know Who You Can Trust.

Get Pre-Launch Early Access: https://signup.tipbros.com/